Elektra Health: Company Overview, Business Model, and Clinical Analysis

What Is Elektra Health?

Elektra Health is a telehealth company built around a single clinical focus: menopause. The platform connects patients with providers who specialize in perimenopause and postmenopause care, offering virtual visits, prescription management, and structured education programs. Unlike general-purpose telehealth services that treat menopause as one condition among hundreds, Elektra positions itself as a specialty destination.

The company was founded in 2019 by Alessandra Henderson after she observed a gap between the number of women experiencing menopause symptoms and the number of clinicians trained to treat them. That gap is real. A 2023 survey published in Mayo Clinic Proceedings found that only 31.8% of OB-GYN residency programs offered any menopause medicine curriculum, and fewer than 1 in 5 residents felt "adequately prepared" to manage hormone therapy [1]. The Menopause Society (formerly NAMS) has certified approximately 1,500 practitioners in the United States, serving a population of roughly 55 million women aged 40 to 65 [2].

Elektra's clinical model attempts to address this shortage by concentrating menopause-trained providers on a single platform. Patients can book individual virtual consultations for symptom assessment, lab review, and prescribing. The company also runs group sessions covering topics like vasomotor symptom management, sleep disruption, and vaginal health.

How Does the Business Model Work?

Elektra Health operates a hybrid payment model that accepts commercial insurance for eligible members while offering a direct-pay option for patients without qualifying coverage. The insurance pathway covers consultations at standard copay or coinsurance rates, depending on the patient's plan. Cash-pay pricing for individual consultations has typically ranged from $199 to $299 per visit based on publicly listed rates, though the company has periodically restructured its pricing tiers.

This hybrid approach distinguishes Elektra from purely cash-pay menopause platforms. Insurance acceptance lowers the out-of-pocket barrier for patients whose plans are in-network, while cash-pay ensures access for those outside Elektra's insurance contracts. The tradeoff: insurance-based visits may involve longer scheduling lead times, and not all services (particularly group education) are covered under every plan.

Revenue also flows from employer partnerships. Elektra contracts with self-insured employers to offer menopause care as a covered benefit. A 2023 report from the Mayo Clinic estimated that menopause-related productivity loss costs U.S. employers approximately $1.8 billion per year in missed workdays alone, with total economic burden reaching $26.6 billion annually when including medical spending and reduced work capacity [3]. Employer-sponsored menopause benefits have gained traction partly because of data like this.

The company does not operate its own pharmacy. Prescriptions are sent to the patient's preferred retail or mail-order pharmacy. Medication costs are separate from visit fees.

What Does Elektra Health Prescribe?

Elektra's prescribing scope covers FDA-approved hormone therapy formulations, non-hormonal prescription alternatives, and adjunctive medications for menopause-associated conditions. Their providers follow The Menopause Society's 2022 position statement, which recommends hormone therapy as the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause in appropriate candidates [4].

Specific prescribing categories include:

Systemic hormone therapy. Oral and transdermal estradiol, combined estrogen-progestogen formulations, and micronized progesterone. The Endocrine Society's 2015 guideline on menopause management recommends transdermal estradiol over oral formulations for women with elevated cardiovascular or thromboembolic risk, and Elektra's providers can select between routes based on patient history [5].

Low-dose vaginal estrogen. Vaginal estradiol creams, tablets, and rings for genitourinary syndrome of menopause. The FDA's labeling for these products permits use without concurrent progestogen in women with an intact uterus when formulations are truly low-dose and locally acting [6].

Non-hormonal alternatives. Fezolinetant (Veozah), an NK3 receptor antagonist FDA-approved in May 2023 for moderate-to-severe vasomotor symptoms, represents the first mechanistically novel non-hormonal option in this space. The SKYLIGHT 2 trial (N=501) demonstrated a 61.3% reduction in moderate-to-severe hot flash frequency at 12 weeks with fezolinetant 45 mg vs. 42.4% with placebo [7]. Elektra providers can also prescribe paroxetine 7.5 mg (Brisdelle), the only SSRI with an FDA-approved menopause indication, along with off-label options like venlafaxine, gabapentin, and clonidine.

Adjunctive prescriptions. Sleep aids, vaginal moisturizers requiring a prescription, and ospemifene (Osphena) for dyspareunia.

One prescribing limitation: Elektra does not compound custom hormone formulations. Patients seeking compounded bioidentical hormone therapy (cBHT) would need a separate provider. The National Academies of Sciences, Engineering, and Medicine's 2020 report concluded that cBHT has not been shown to be safer or more effective than FDA-approved alternatives, so this omission aligns with evidence-based practice [8].

Is Elektra Health Legit? Clinical Evidence Behind Their Approach

The clinical framework Elektra uses is grounded in established guidelines. Their stated alignment with The Menopause Society's recommendations is verifiable through their published treatment protocols and provider credentialing. This matters because menopause care has a long history of misinformation, particularly around the risks of hormone therapy.

The Women's Health Initiative (WHI) trial, first reported in 2002, triggered a sharp decline in hormone therapy use after initial results showed increased breast cancer and cardiovascular events in the estrogen-plus-progestin arm [9]. But 20 years of follow-up data have substantially changed the risk-benefit calculus. The WHI's 2017 cumulative follow-up analysis (N=27,347; median 18 years of follow-up) found that all-cause mortality did not differ between hormone therapy and placebo groups, and that women who initiated estrogen-alone therapy in their 50s had a non-significant trend toward reduced coronary heart disease [10].

The Menopause Society's 2022 position statement explicitly states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms" [4]. This "timing hypothesis" is the backbone of modern prescribing decisions, and Elektra's intake process screens for age, time since menopause onset, and contraindications before recommending hormone therapy.

Provider credentialing adds another layer of legitimacy. Elektra requires its clinicians to hold board certification in a relevant specialty and prioritizes those with NCMP (NAMS Certified Menopause Practitioner) designation. Given that only about 1,500 active NCMP-certified practitioners exist nationwide, this is a meaningful differentiator [2].

Patient satisfaction data is harder to assess independently. Elektra publishes testimonials on its website, but no peer-reviewed outcomes data from the platform itself has appeared in indexed medical literature as of this writing. This is not unusual for telehealth companies at Elektra's stage, but it does mean that claims about clinical outcomes rely on guideline adherence rather than proprietary outcome tracking.

Elektra Health vs. Alternatives

Several telehealth platforms now target the menopause market. Comparing them requires evaluating five dimensions: prescribing scope, payment model, provider specialization, state coverage, and ancillary services.

Elektra Health vs. Midi Health. Midi Health is Elektra's closest competitor. Both focus exclusively on menopause, accept insurance, and employ menopause-specialized providers. Midi covers a broader geographic footprint as of early 2026 and has published more extensively on its clinical model, including a retrospective cohort study demonstrating improvement in menopause symptom scores across 10,000+ patients [11]. Elektra's group education component and employer partnership model differentiate it, but Midi's clinical data transparency gives it an edge for evidence-minded patients.

Elektra Health vs. Alloy Health. Alloy operates a simpler direct-to-consumer model focused on shipping FDA-approved HRT products. It does not accept insurance. Alloy bundles medication and provider consultations into a subscription price, which creates cost predictability but limits formulary flexibility. Alloy suits patients who know what they want. Elektra suits patients who need a diagnostic workup.

Elektra Health vs. general telehealth (Teladoc, Hers, etc.). General telehealth platforms can prescribe hormone therapy, but their providers typically lack menopause subspecialization. A patient seeing a generalist through Hers may receive appropriate treatment, but complex cases involving prior breast cancer history, VTE risk assessment, or treatment failure triage benefit from the focused expertise Elektra and Midi concentrate.

Elektra Health vs. in-person menopause specialists. An in-person NCMP-certified provider remains the gold standard for initial evaluation, particularly when pelvic exams, DEXA scans, or hands-on assessment of vaginal atrophy severity are needed. Elektra cannot perform physical examinations. For straightforward vasomotor symptom management in otherwise healthy women within the "timing window," virtual care is clinically appropriate per the American College of Obstetricians and Gynecologists' telehealth guidance [12].

Cost Structure and Insurance Details

The total cost of using Elektra Health depends on three variables: visit fees, medication costs, and lab work. Visit fees are the only component Elektra controls directly.

For insured patients, visit copays follow standard specialist rates under the patient's plan, typically $30 to $75 per visit depending on the insurer. Elektra is in-network with select commercial plans; their website lists currently accepted insurers, but this changes as contracts are renegotiated.

Cash-pay patients face higher per-visit costs. Published rates have historically sat between $199 and $299 for an initial consultation, with follow-up visits priced somewhat lower. Membership or subscription models have been tested at various points, bundling a set number of visits and messaging access for a monthly fee.

Medication costs are independent of Elektra. Generic transdermal estradiol patches cost approximately $15 to $50 per month at retail pharmacies with a GoodRx coupon. Oral micronized progesterone (generic Prometrium) runs $10 to $30 per month. Brand-name options like the Climara patch or the Bijuva capsule can exceed $200 per month without insurance. Fezolinetant (Veozah) carries a list price of approximately $550 per month, though manufacturer copay programs may reduce this [13].

Lab work ordered by Elektra providers is processed through standard reference labs. Patients with insurance typically pay lab costs at their plan's contracted rate. Cash-pay patients should expect $50 to $200 for a standard hormone panel (FSH, estradiol, thyroid function) depending on the lab.

Limitations Worth Knowing

Elektra does not perform physical examinations, which limits its utility for conditions requiring hands-on assessment. Breast exams, pelvic exams, and bone density screening must happen through a separate provider. The platform also does not prescribe testosterone for women, a treatment that some menopause specialists use off-label for hypoactive sexual desire disorder based on the 2019 global consensus position published in The Journal of Clinical Endocrinology & Metabolism [14]. Patients seeking testosterone therapy would need to look elsewhere.

State-by-state availability is another constraint. Telehealth licensing requirements mean that Elektra cannot serve patients in every state. The company does not always publish its full coverage map prominently, so prospective patients should verify availability before scheduling.

Response times for asynchronous messaging vary. During periods of high demand, patients have reported wait times of several days for non-urgent messages. This is a common telehealth pain point, not specific to Elektra, but it is worth setting expectations.

The absence of published outcomes data from Elektra's own patient population is a gap. Midi Health's decision to publish retrospective cohort data [11] sets a benchmark that Elektra has not yet matched. Guideline adherence is necessary but not sufficient for demonstrating real-world effectiveness. Publication of de-identified outcome metrics (symptom score changes, treatment persistence rates, adverse event frequency) would strengthen Elektra's credibility in a competitive market.

Who Benefits Most from Elektra Health?

The patients most likely to benefit from Elektra Health share a specific profile: they are experiencing bothersome vasomotor symptoms or genitourinary symptoms, they are within the guideline-recommended window for hormone therapy initiation (under 60 or within 10 years of menopause onset), they lack access to a local menopause specialist, and they prefer virtual care. The platform is less suited for patients with complex medical histories requiring in-person evaluation, those seeking compounded hormones, or those in states where Elektra does not operate.

For employers evaluating menopause benefits, Elektra's model provides a structured, guideline-aligned care pathway that can be offered alongside existing health plan coverage. The economic argument is straightforward: the Mayo Clinic's 2023 analysis estimated 13.9 million workdays lost annually due to menopause symptoms, with $1.8 billion in direct lost-workday costs [3]. A benefit that reduces symptom burden could recoup a measurable fraction of that loss.

The Menopause Society recommends annual reassessment of hormone therapy with shared decision-making at each visit [4]. Patients using Elektra should expect ongoing follow-up visits, not a single consultation and indefinite refills.